{"id":39484,"date":"2026-08-03T09:59:16","date_gmt":"2026-08-03T07:59:16","guid":{"rendered":"https:\/\/ggba.swiss\/?p=39484"},"modified":"2026-08-03T09:59:17","modified_gmt":"2026-08-03T07:59:17","slug":"pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/","title":{"rendered":"Pilatus Biosciences takes its Lausanne-born immunotherapy to Hong Kong"},"content":{"rendered":"\n<p><a href=\"https:\/\/www.pilatusbio.com\/\">Pilatus Biosciences<\/a>, which develops metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, has received the Certificate for Clinical Trial \/ Medicinal Test from the Hong Kong Department of Health for its lead investigational therapy, PLT012, in patients with advanced solid tumors. The company has also established a Hong Kong subsidiary.<\/p>\n\n\n\n<p>PLT012 is a first-in-class therapeutic targeting CD36, a key regulator of metabolic dysfunction and inflammation. The program is being developed for indications where modulation of CD36 has the potential to improve patient outcomes. The study will be conducted at the Phase I Clinical Trial Centre, under the Department of Clinical Oncology of The Chinese University of Hong Kong, with Dr. Stephen Chan as principal investigator.<\/p>\n\n\n\n<p>The new subsidiary expands the company&#8217;s presence in one of Asia&#8217;s leading biotechnology and clinical-research hubs. Pilatus plans to draw on the territory&#8217;s life sciences ecosystem to support clinical development, academic and strategic collaborations, and engagement with regional investors.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pilatus Biosciences, a Biop\u00f4le-based biotech whose lead therapy originated in research conducted in Lausanne, has established a subsidiary in Hong Kong and received regulatory approval to begin a clinical trial of PLT012 in patients with advanced solid tumors.<\/p>\n","protected":false},"author":6,"featured_media":39485,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,890,883],"class_list":["post-39484","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-healthcare","tag-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pilatus Biosciences expands into Hong Kong | GGBa<\/title>\n<meta name=\"description\" content=\"Pilatus Biosciences has established a Hong Kong subsidiary and received approval to start a clinical trial of its lead therapy PLT012.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pilatus Biosciences expands into Hong Kong | GGBa\" \/>\n<meta property=\"og:description\" content=\"Pilatus Biosciences has established a Hong Kong subsidiary and received approval to start a clinical trial of its lead therapy PLT012.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-03T07:59:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-03T07:59:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Pilatus-Bio-Hong-Kong-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Pilatus Biosciences takes its Lausanne-born immunotherapy to Hong Kong\",\"datePublished\":\"2026-08-03T07:59:16+00:00\",\"dateModified\":\"2026-08-03T07:59:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/\"},\"wordCount\":165,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Pilatus-Bio-Hong-Kong-1180x811-1.jpeg\",\"keywords\":[\"Biotech\",\"Healthcare\",\"Oncology\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/\",\"url\":\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/\",\"name\":\"Pilatus Biosciences expands into Hong Kong | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Pilatus-Bio-Hong-Kong-1180x811-1.jpeg\",\"datePublished\":\"2026-08-03T07:59:16+00:00\",\"dateModified\":\"2026-08-03T07:59:17+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Pilatus Biosciences has established a Hong Kong subsidiary and received approval to start a clinical trial of its lead therapy PLT012.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Pilatus-Bio-Hong-Kong-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Pilatus-Bio-Hong-Kong-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"Pilatus Biosciences develops metabolic checkpoint immunotherapies based on research carried out at the Ludwig Institute for Cancer Research in Lausanne. | \u00a9 Pilatus Biosciences\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pilatus Biosciences takes its Lausanne-born immunotherapy to Hong Kong\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pilatus Biosciences expands into Hong Kong | GGBa","description":"Pilatus Biosciences has established a Hong Kong subsidiary and received approval to start a clinical trial of its lead therapy PLT012.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/","og_locale":"en_US","og_type":"article","og_title":"Pilatus Biosciences expands into Hong Kong | GGBa","og_description":"Pilatus Biosciences has established a Hong Kong subsidiary and received approval to start a clinical trial of its lead therapy PLT012.","og_url":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2026-08-03T07:59:16+00:00","article_modified_time":"2026-08-03T07:59:17+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Pilatus-Bio-Hong-Kong-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Pilatus Biosciences takes its Lausanne-born immunotherapy to Hong Kong","datePublished":"2026-08-03T07:59:16+00:00","dateModified":"2026-08-03T07:59:17+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/"},"wordCount":165,"image":{"@id":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Pilatus-Bio-Hong-Kong-1180x811-1.jpeg","keywords":["Biotech","Healthcare","Oncology"],"articleSection":["Life sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/","url":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/","name":"Pilatus Biosciences expands into Hong Kong | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Pilatus-Bio-Hong-Kong-1180x811-1.jpeg","datePublished":"2026-08-03T07:59:16+00:00","dateModified":"2026-08-03T07:59:17+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Pilatus Biosciences has established a Hong Kong subsidiary and received approval to start a clinical trial of its lead therapy PLT012.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Pilatus-Bio-Hong-Kong-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Pilatus-Bio-Hong-Kong-1180x811-1.jpeg","width":1180,"height":811,"caption":"Pilatus Biosciences develops metabolic checkpoint immunotherapies based on research carried out at the Ludwig Institute for Cancer Research in Lausanne. | \u00a9 Pilatus Biosciences"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/pilatus-biosciences-takes-its-lausanne-born-immunotherapy-to-hong-kong\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Pilatus Biosciences takes its Lausanne-born immunotherapy to Hong Kong"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/39484","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=39484"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/39484\/revisions"}],"predecessor-version":[{"id":39488,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/39484\/revisions\/39488"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/39485"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=39484"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=39484"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=39484"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}